Safety, tolerability and pharmacokinetics of PL 14736, a novel agent for treatment of ulcerative colitis, in healthy male volunteers. (CROSBI ID 491171)
Prilog sa skupa u zborniku | sažetak izlaganja sa skupa | međunarodna recenzija
Podaci o odgovornosti
Veljača, Marija ; Pavić-Sladoljev, D. ; Mildner, Boris ; Brajša, Karmen ; Krnić, Žarka ; Bubenik, M. ; Stipaničić, S. ; Tabak-Slošić, Maja ; Brnić, L. ; Khan, Z. ; Krznarić, Željko ; Bischoff, A. ; Scroeder, A. ; van Dongen, W.D. ; van Schaik, F.
engleski
Safety, tolerability and pharmacokinetics of PL 14736, a novel agent for treatment of ulcerative colitis, in healthy male volunteers.
PL 14736, a novel 15 amino acid peptide, has shown benefical activity in experimental models of gastrointestinal damage. Seven-day intracolonic administration of PL 14736 to rats has significantly reduced the extent TNBS-induced colonic damage and hastened healing. These results have encuraged the development of the compound for the treatment of patients with ulcerative colitis. In this first study in man, rectal administration of PL 14736 to healthy male volunteers was safe and well tolerated. Based on these data, a randomized, double-blind, placebo-controlled study was started in order to investigate the tolerabillity and efficacy of Pl 14736 enemas in patients with acute mild to moderate ulcerative colitis
ulcerative colitis; PL 14736; phase I clinical testing
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
Podaci o prilogu
74-75.
2002.
objavljeno
Podaci o matičnoj publikaciji
Abstracts of the 6th ESGENA Conference and 10th United European Gastroentherology Week : UEGW u: European Journal of Pharmaceutical Sciences (ISSN 0928-0987) 17 (2002) (Sl)
Podaci o skupu
United European Gastroentherology Week (10 ; 2002)
poster
01.01.2002-01.01.2002
Ženeva, Švicarska